Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Questcor Pharmaceuticals ( QCOR) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 2.2%. By the end of trading, Questcor Pharmaceuticals rose $1.09 (1.3%) to $84.24 on light volume. Throughout the day, 1,217,781 shares of Questcor Pharmaceuticals exchanged hands as compared to its average daily volume of 3,066,700 shares. The stock ranged in a price between $82.11-$85.00 after having opened the day at $82.67 as compared to the previous trading day's close of $83.15. Other companies within the Drugs industry that increased today were: Sagent Pharmaceuticals ( SGNT), up 9.7%, Nanoviricides ( NNVC), up 8.2%, Vivus ( VVUS), up 7.2% and XTL Biopharmaceuticals ( XTLB), up 4.6%.

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides drugs for the treatment of autoimmune and inflammatory disorders. The company primarily offers H.P. Questcor Pharmaceuticals has a market cap of $5.1 billion and is part of the health care sector. The company has a P/E ratio of 15.6, below the S&P 500 P/E ratio of 17.7. Shares are up 52.7% year to date as of the close of trading on Monday. Currently there are 3 analysts that rate Questcor Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Questcor Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the negative front, Aoxing Pharmaceutical ( AXN), down 10.6%, BioTime ( BTX), down 9.3%, Achaogen ( AKAO), down 9.3% and Fibrocell Science ( FCSC), down 8.6% , were all laggards within the drugs industry with Forest Laboratories ( FRX) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.